Actively Recruiting
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Led by Tanta University · Updated on 2023-11-18
50
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.
CONDITIONS
Official Title
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of stage IV (metastatic) colorectal cancer documented by all investigating parameters
- Male or female patients aged between 18 and 65 years old
- Women of childbearing age must use acceptable contraception
- Performance status less than 2 according to the Eastern Cooperative Oncology Group (ECOG) score
- No contraindication to chemotherapy, including absence of myelosuppression
- Adequate liver function with ALT and AST less than grade 2 per NCI-CTCAE v5.0
- Adequate renal function with estimated creatinine clearance and serum creatinine less than grade 2 per NCI-CTCAE v5.0
- Adequate hematological parameters (hemoglobin, erythrocytes, platelets, leukocytes, and absolute neutrophil count) less than grade 2 per NCI-CTCAE v5.0
You will not qualify if you...
- Pregnant or lactating women
- Patients with active cancer from a primary site other than colon or rectum
- Known allergy to sulfasalazine or its metabolites
- Patients with nephrolithiasis, severe vomiting, or severe diarrhea
- Receiving highly plasma protein-bound drugs or drugs with extensive hepatic metabolism such as coumarin anti-coagulants
- Patients with intestinal or urinary obstruction
- Known glucose-6-phosphate dehydrogenase deficiency or porphyria
- Ongoing treatment with sulfasalazine or mesalamine for ulcerative colitis or rheumatoid arthritis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University Hospital
Tanta, El-Gharbia Governorate, Egypt, 31527
Actively Recruiting
Research Team
R
Reham A. El-Ghoneimy, M.Sc in Clinical Pharmacy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here